<DOC>
	<DOCNO>NCT00124618</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving cetuximab together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together radiation therapy work treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Cetuximab Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary * Determine 11 month survival rate old and/or poor performance status patient stage IIIA stage IIIB non-small cell lung cancer treat cetuximab radiotherapy . Secondary - Determine tumor response rate , overall survival , time disease progression patient treat regimen . - Determine toxicity regimen patient . - Determine whether fear death less severe old patient treat regimen . - Determine whether fear death predicts survival patient treat regimen . OUTLINE : This multicenter study . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Beginning day 8 , patient receive concurrent radiotherapy daily day 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow within 1 week , 1 4 month , every 3 month 3 year . PROJECTED ACCRUAL : A total 60 patient accrue study within 20 month</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIA IIIB disease Must candidate curative radiotherapy Not candidate concurrent chemotherapy radiotherapy No surgical treatment available No pleural effusion suspect proven malignant No stage IV disease bone scan positron emission tomography scan , CT scan MRI brain , CT scan chest within past 30 day PATIENT CHARACTERISTICS : Age * 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 ( age ≥ 65 year ) ECOG 2 ( age 18 64 year ) Life expectancy * At least 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ≤ 3 time ULN Renal Creatinine ≤ 1.5 time ULN Pulmonary FEV_1 ≥ 1 L No idiopathic pulmonary fibrosis Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Magnesium normal No uncontrolled infection No severe underlie disease would preclude study entry No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer noninvasive carcinoma No major psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy * Not specify Chemotherapy See Disease Characteristics No prior chemotherapy NSCLC Endocrine therapy * Not specify Radiotherapy No prior therapeutic radiotherapy chest No concurrent intensity modulate radiotherapy Other * No prior epidermal growth factor receptor inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>